Pradaxa Lawsuit News and Information
Pradaxa Internal Bleeding Lawsuit
The new blood thinner Pradaxa has been linked to an increased risk of serious and potentially life-threatening bleeding, leading many to question its safety. PRADAXA LAWSUIT STATUS: Users of Pradaxa who suffered severe internal bleeding, hemorrhages or other problems may be eligible to pursue a Pradaxa lawsuit. Lawyers are reviewing potential claims for individuals throughout [...]
All Articles Tagged With: "Pradaxa"
Lack of Reversal Agent May Raise Pradaxa Brain Bleed Risks: Studies
New research that examines the risk of brain bleeding on Pradaxa highlights the lack of effective medical strategies available to stop the blockbuster drug’s anticoagulant effects.
Pradaxa Warning Label Updated by Boehringer Ingelheim
The warning label for Pradaxa is being updated, indicating that patients who are at risk of stroke should not stop using the anticogulant without talking to their doctor first. The changes come amid continuing debate over the safety of the drug and concerns about Pradaxa bleeding risks in the scientific and regulatory communities.
New Blood Thinner Reversal Agent Won’t Work With Pradaxa, Xarelto
Federal drug regulators have approved the use of a reversal agent for anticoagulation therapy, which will be marketed as Kcentra. The drug is designed to help prevent patients given Coumadin or its generic equivalent, warfarin, from bleeding to death. However, the reversal agent will not work with a newer class of anticoagulants, including Pradaxa and [...]
Despite Bleeding Problems and Lawsuits, Pradaxa Sales Hit $1.43B
Despite reports of uncontrolled hemorrhages and a growing number of Pradaxa lawsuits filed over the manufacturer’s failure to adequately warn about the lack of a reversal agent to stop bleeding problems that may develop, Boehringner Ingelheim’s new anticoagulant has achieved blockbuster status in the second full year on the market.
Process Established for Selection of Pradaxa Cases for Early Trials in MDL
The U.S. District Judge presiding over all federal Pradaxa cases has established guidelines for selecting a series of “bellwether” trials, involving lawsuits that allege the manufacturers of the anticoagulant failed to adequately warn about the side effects of Pradaxa.
Avoid Pradaxa, Xarelto Due to Emerging Health Risks: Public Citizen
The prominent watchdog group Public Citizen is warning consumers to stay away from a new class of anticoagulants that includes Pradaxa and Xarelto, indicating that there is increasing evidence of severe bleeding issues with the drugs and a lack of information to establish that they are superior to warfarin, which has been the go-to stroke [...]
Pradaxa Side Effects May Increase Infection Risk: Study
New research suggests that side effects of Pradaxa, a relatively new anticoagulant, may leave users more vulnerable to viral infections, including one that is often fatal for children and young adults.
Pradaxa Bleeding Reports Provide ‘Distorted Estimate’ of Risk: FDA Staff
Federal health officials are suggesting that the recent surge in adverse event reports involving bleeding problems with Pradaxa, an anticoagulant that has been linked to thousands of cases involving uncontrollable hemorrhages, may be exaggerated due to a greater likelihood for doctors and patients to report issues with the relatively new medication.
FDA Rejects New Use for Xarelto, Cites Bleeding Risks
The FDA cited the increased risk of severe bleeding as one of the reasons for rejecting an attempt by Bayer and Johnson & Johnson to expand the use of their blood thinner Xarelto for prevention of heart attacks and strokes among patients with existing heart problems.
Pradaxa Bleeding Death Five Times More Likely Than With Warfarin: Report
According to a review of adverse event reports submitted to the FDA, Pradaxa bleeding problems appear to be five times more likely to result in death than those associated with warfarin, a much older blood thinner.
Contact a Lawyer
Submit information about your potential case to be reviewed by an attorney.
